Similar approaches can be applied to cervical cancer, where a transient receptor potential vanilloid 1 (TRPV1) inhibitor may enhance the efficacy of existing treatments and potentially overcome resistance to cisplatin therapy [96]. This evidence concerns the gene TRPV1 and cervical carcinoma.